Oncolytic parvoviruses as cancer therapeutics.

Abstract : The experimental infectivity and excellent tolerance of some rodent autonomous parvoviruses in humans, together with their oncosuppressive effects in preclinical models, speak for the inclusion of these agents in the arsenal of oncolytic viruses under consideration for cancer therapy. In particular, wild-type parvovirus H-1PV can achieve a complete cure of various tumors in animal models and kill tumor cells that resist conventional anticancer treatments. There is growing evidence that H-1PV oncosuppression involves an immune component in addition to the direct viral oncolytic effect. This article summarizes the recent assessment of H-1PV antineoplastic activity in glioma, pancreatic ductal adenocarcinoma, and non-Hodgkin lymphoma models, laying the foundation for the present launch of a first phase I/IIa clinical trial on glioma patients.
Document type :
Journal articles
Complete list of metadatas

Cited literature [49 references]  Display  Hide  Download

https://hal-riip.archives-ouvertes.fr/pasteur-00748225
Contributor : Petar Grozdanov <>
Submitted on : Monday, November 5, 2012 - 10:45:39 AM
Last modification on : Thursday, June 6, 2019 - 3:26:02 PM
Long-term archiving on : Saturday, December 17, 2016 - 8:17:09 AM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

Citation

Jean Rommelaere, Karsten Geletneky, Assia L Angelova, Laurent Daeffler, Christiane Dinsart, et al.. Oncolytic parvoviruses as cancer therapeutics.. Cytokine and Growth Factor Reviews, Elsevier, 2010, 21 (2-3), pp.185-95. ⟨10.1016/j.cytogfr.2010.02.011⟩. ⟨pasteur-00748225⟩

Share

Metrics

Record views

212